1. Pink Sheet
  2. >>Pathways & Standards
  3. >>Review Pathways

Rare Pediatric Disease Priority Review Voucher Not Generating New Drug Trials

 
• By Derrick Gingery

Researchers find no significant difference in number of rare pediatric disease treatments starting clinical development before or after incentive was created, but advocates aren't ready to give up on the program yet.

incentive business concept as a group of businessmen and businesswomen run on a track towards a dangling carrot on a moving cable
Are there more trials on the track now that there's a PRV carrot at the end?

The US rare pediatric disease priority review voucher has not caused more drugs in the sector to reach clinical testing stages, adding to ongoing criticism of the program and potentially complicating its upcoming renewal.

Thomas Hwang, Florence Bourgeois, Jessica Franklin, and Aaron Kesselheim, all of Harvard Medical School, published a study in the February issue of Health Affairs exploring the number of potentially voucher-eligible treatments in the clinical development pipeline before the program was created in 2012, as well as after it launched

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Review Pathways

More from Pathways & Standards